Another Biogen-Ionis collab hits the dust after phase 1 ALS flopnews2022-03-28T14:38:21+00:00March 28th, 2022|FierceBiotech|
Verastem takes on debt to get RAS tumor program to finish linenews2022-03-28T12:17:43+00:00March 28th, 2022|FierceBiotech|
Lilly, after making $1B bet, posts ‘compelling’ late-phase data on Dupixent rivalnews2022-03-28T10:12:53+00:00March 28th, 2022|FierceBiotech|
Icosavax’s COVID-19 shot fails to deliver in early data, spurring debate about ‘fatal flaw’ in platformnews2022-03-25T14:18:34+00:00March 25th, 2022|FierceBiotech|
89bio gains a little more confidence in NASH treatment with new hormone datanews2022-03-25T13:54:25+00:00March 25th, 2022|FierceBiotech|
AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizernews2022-03-25T11:50:18+00:00March 25th, 2022|FierceBiotech|
MEI rocked as FDA request for randomized data on cancer drug ends hopes of accelerated approval news2022-03-25T09:26:32+00:00March 25th, 2022|FierceBiotech|
Chutes & Ladders—After 9 years at Merck, Roy Baynes follows Roger Perlmutter to Eikonnews2022-03-24T18:03:03+00:00March 24th, 2022|FierceBiotech|
Ligand takes a crack at a SPAC to buoy spun-off antibody discovery businessnews2022-03-24T15:12:04+00:00March 24th, 2022|FierceBiotech|
Homology gets clarity on how to resolve pheNIX gene therapy holdnews2022-03-24T14:22:04+00:00March 24th, 2022|FierceBiotech|
